Table 3.
The COMT rs4680 genotype count and frequencies in schizophrenia patients treated with olanzapine, risperidone, clozapine or other antipsychotics, subdivided into responders (R) and non-responders (NR) according to the 50% reduction in the baseline PANSS0–6 total and subscale scores.
| COMT rs4680 | Olanzapine n = 190 |
Risperidone n = 99 |
Clozapine n = 102 |
Other antipsychotics n = 130 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | AA | AG | GG | AA | AG | GG | AA | AG | GG | ||
| Total PANSS0–6 score reduction at week 8 | NR | 17 (22.4) | 35 (46.1) | 24 (31.6) | 13 (34.2) | 15 (39.5) | 10 (26.3) | 13 (24.1) | 26 (48.1) | 15 (27.8) | 13 (27.1) | 21 (43.8) | 14 (29.2) |
| R | 29 (25.4) | 64 (56.1) | 21 (18.4) | 13 (21.3) | 31 (50.8) | 17 (27.9) | 13 (27.1) | 22 (45.8) | 13 (27.5) | 17 (20.7) | 44 (53.7) | 21 (25.6) | |
| χ2 = 4.40; p = 0.111 | χ2 = 2.15; p = 0.341 | χ2 = 0.12; p = 0.940 | χ2 = 1.27; p = 0.753 | ||||||||||
| PANSS0–6 positive scores reduction at week 8 | NR | 12 (23.1) | 22 (42.3) | 18 (34.6) | 9 (32.1) | 12 (42.9) | 7 (25.0) | 8 (22.2) | 16 (44.4) | 12 (33.3) | 10 (25.6) | 17 (43.6) | 12 (30.8) |
| R | 34 (34.6) | 77 (55.8) | 27 (19.6) | 17 (23.9) | 34 (47.9) | 20 (28.2) | 18 (27.3) | 32 (48.5) | 16 (24.2) | 20 (22.0) | 48 (52.7) | 23 (25.3) | |
| χ2 = 4.97; p = 0.083 | χ2 = 0.70; p = 0.706 | χ2 = 1.02; p = 0.602 | χ2 = 0.92; p = 0.630 | ||||||||||
| PANSS0–6 negative scores reduction at week 8 | NR | 31 (25.2) | 57 (46.3) | 35 (28.5) | 17 (30.9) | 23 (41.8) | 15 (27.3) | 22 (25.3) | 41 (47.1) | 24 (27.6) | 16 (23.2) | 33 (47.8) | 20 (29.0) |
| R | 15 (22.4) | 42 (62.7) | 10 (14.9) | 9 (20.5) | 23 (52.3) | 12 (27.3) | 4 (26.7) | 7 (46.7) | 4 (26.7) | 14 (23.0) | 32 (52.5) | 15 (24.6) | |
| χ2 = 5.72; p = 0.057 | χ2 = 1.59; p = 0.451 | χ2 = 0.01; p = 0.993 | χ2 = 0.37; p = 0.830 | ||||||||||
| PANSS0–6 general psychopathology scores reduction at week 8 | NR | 22 (26.5) | 36 (43.4) | 25 (30.1) | 13 (31.0) | 17 (40.5) | 12 (28.6) | 11 (19.3) | 29 (50.9) | 17 (29.8) | 17 (28.8) | 25 (42.4) | 17 (28.8) |
| R | 24 (22.4) | 63 (58.9) | 20 (18.7) | 13 (22.8) | 29 (50.9) | 15 (26.3) | 15 (33.3) | 19 (42.2) | 11 (24.4) | 13 (18.3) | 40 (56.3) | 18 (25.4) | |
| χ2 = 5.06; p = 0.080 | χ2 = 1.22; p = 0.544 | χ2 = 2.61; p = 0.271 | χ2 = 2.94; p = 0.230 | ||||||||||
Frequencies (%) are shown in parenthesis.
n number of subjects, NR non-responders, PANSS positive and negative syndrome scale, R responders.